Trevi Therapeutics (NASDAQ:TRVI) Stock

TREVI THERAPEUTICS INC

Trevi Therapeutics

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Trevi Therapeutics Inc

H&amp;R REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/HR#TSX">HR</a>) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.29 by 2.41 percent. This is a 1 percent decrease over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $205.64 million which missed the analyst consensus estimate of $236.60 million by 13.09 percent. This is a 1.85 percent decrease over sales of $209.52 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

TSX:HR

H&R REIT Q1 FFO $0.30 Beats $0.29 Estimate, Sales $205.64M Miss $236.60M Estimate

WIIM

ICCC

ImmuCell shares are trading higher after the company reported a year-over-year increase in Q1 financial results.

SQFT

Presidio Property Trust Q1 FFO $(0.076) Down From $(0.035) YoY, Sales $4.13M Down From $4.79M YoY

ISSC

Innovative Solutions shares are trading higher after the company reported better-than-expected Q2 financial results.

Lithium Argentina Q1 EPS $(0.04) Misses $(0.01) Estimate

Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) released its third-quarter results after Wednesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/25/05/n45419675/cisco-reports-third-quarter-earnings">details from the report.</a> 
The Details: Cisco reported quarterly earnings of 96 cents per share, which beat the analyst consensus estimate of 92 cents. Quarterly revenue came in at $14.15 billion, which beat the Street estimate of $14.08 billion and is up from revenue of $12.70 billion from the same period last year.
Read Next: <a href="https://www.benzinga.com/news/large-cap/25/05/45414265/nvidia-climbs-on-saudi-ai-investments-analyst-estimates-15-billion-to-20-billion-in-revenue?utm_source=articleShare">Nvidia Climbs On Saudi AI Investments: Analyst Estimates $15 Billion To $20 Billion In Revenue&nbsp;</a>
Cisco also reported product orders were up 20% year-over-year, up 9% excluding Splunk, with growth across all geographies and customer markets. AI Infrastructure orders taken from webscale customers exceeded $600 million, surpassing the company&#8217;s $1 billion target one quarter early. 
&#8220;Cisco once again had strong quarterly results with clear demand for our technologies,&#8221; said Chuck Robbins, chair and CEO of Cisco. &#8220;The momentum we are seeing with AI is fueled by the power of our secure networking portfolio, our trusted global partnerships, and the value we bring to our customers.&#8221;
Outlook:&nbsp;Cisco sees fourth-quarter adjusted earnings of between 96 cents and 98 cents per share, versus the 95 cent estimate, and revenue in a range of $14.5 billion and $14.7 billion, versus the $14.58 billion estimate. 
Cisco raised its fiscal 2025 EPS guidance from between $3.68 and $3.74 per share to between $3.77 and $3.79 per share, versus the $3.73 estimate. The company raised its fiscal 2025 revenue forecast from a range of $56 billion to $56.50 billion to a new range of $56.5 billion to $56.7 billion, versus the $56.47 billion estimate.
CSCO Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Cisco stock was up 3.90% at $63.68 after-hours Wednesday.  
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45353123/quantum-stocks-are-hot-in-2025-biggest-movers-to-watch?utm_source=articleShare">Quantum Stocks Are Hot In 2025: Biggest Movers To Watch&nbsp;</a></li>
</ul>
Photo: Shutterstock

Movers

Tech

CSCO

Cisco Shares Climb After Q3 EPS, Revenue Beat Estimates: Details

FrontView REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FVR#NYSE">FVR</a>) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.28 by 7.14 percent. The company reported quarterly sales of $16.24 million which missed the analyst consensus estimate of $16.33 million by 0.53 percent.

FrontView REIT Q1 FFO $0.30 Beats $0.28 Estimate, Sales $16.24M Miss $16.33M Estimate

CTXR

Citius Pharma Q2 EPS $(1.27) Misses $0.33 Estimate

Retailer Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) may provide a better picture of the impact of tariffs on consumers when the company reports first-quarter financial results before <a href="https://www.benzinga.com/earnings">market open Thursday.</a>
Here are the analyst estimates, a look at what experts are saying ahead of the report and key items to watch.
Earnings Estimates: Analysts expect Walmart to report first-quarter revenue of $165.88 billion. That&#8217;s up from $161.51 billion in last year's first quarter, according to data <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514">from Benzinga Pro.</a>
The company has beaten analyst estimates for revenue in more than 10 straight quarters.
Analysts expect Walmart to report earnings per share of 58 cents, down from 60 cents per share in Q1 2024.
The company has beaten analyst estimates for earnings per share in five straight quarters and nine of the last ten quarters overall. The lone non-beat was earnings in line with estimates.
The company&#8217;s guidance calls for first-quarter sales to be up 3% to 4% year over year. Earnings per share range between 57 cents and 58 cents.
Read Also: <a href="https://www.benzinga.com/politics/25/05/45272436/marjorie-taylor-greene-goes-stock-shopping-again-here-are-50-stocks-the-congresswoman-bought">Marjorie Taylor Greene Goes Stock Shopping Again: 50+ Stocks The Congresswoman Bought</a>
What Experts Are Saying: In a recent note, Telsey Advisory analyst Joseph Feldman said Walmart could benefit from grocery market share gains and improving e-commerce progress in the <a href="https://www.benzinga.com/news/large-cap/25/05/45357178/walmart-analysts-strategy-curbs-price-hikes-despite-tariffs">first quarter.</a>
The analyst maintained an Outperform rating and price target for $115.
Feldman said Walmart could gain wallet share from several groups, including higher-income consumers. The analyst said Amazon and Costco showed trends of first-quarter sales being stronger for categories like electronics.
Feldman said Walmart should navigate the uncertain macroeconomic environment effectively.
Bank of America analyst Robert Ohmes said Walmart is well-equipped to handle tariffs with its pricing and automation strategies, inventory management and strong supplier relationships.
The analyst maintained a Buy rating with a $120 price target ahead of the quarterly earnings.
Ohmes said Walmart's groceries are less likely to be impacted by tariffs.
Freedom Capital Markets Chief Global Strategist Jay Woods highlighted the importance of Walmart's financial results for the market in his weekly <a href="https://jaywoods.substack.com/">newsletter</a>.
"Walmart could be one of the most telling stocks when it comes to tariff impacts when they report on Thursday," Woods said.
Woods said Walmart was cautious with guidance after the last quarter.
"Investors will be closely watching this report for strategies on managing tariff-related challenges, maintaining competitive pricing, and supply chain issues that may make stocking shelves more of a challenge."
Key Items to Watch: Tariffs commentary will undoubtedly be the biggest item in Walmart's earnings and conference call.
Outside of tariffs, investors and analysts could also look at commentary on the company's Walmart+ membership program. The subscription-based service was responsible for around 50% of online spending in the U.S. last fiscal year. This could make it a strong source of ecommerce and recurring revenue.
A report said the program is seeing increased spending per subscriber and also higher shopping frequency rates from subscribers.
Walmart+ has also helped the retailer post 11 consecutive quarters of double-digit online sales growth in the United States.
Global e-commerce sales were up 16% year-over-year in Q4; this will be a key area to watch in Q1.
WMT Price Action: Walmart stock was up 1.3% to $97.11 on Wednesday versus a 52-week trading range of $59.47 to $105.30. Walmart stock is up 7.9% year-to-date in 2025 and up over 60% in the last year. 
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/25/03/44226602/walmart-ceo-says-consumers-changing-spending-due-to-inflation-egg-prices-the-money-runs-out-before-the-month-is-gone-people-are-buying-smaller-pack-sizes">Walmart CEO Says Consumers Changing Spending Due To Inflation, Egg Prices: &#8216;The Money Runs Out Before The Month Is Gone … People Are Buying Smaller Pack Sizes&#8217;</a><a href="https://www.benzinga.com/go/plus500-futures" target="_blank" rel="noreferrer noopener"></a></li>
</ul>
Image: Shutterstock<a href="https://www.benzinga.com/go/plus500-futures" target="_blank" rel="noreferrer noopener"> </a>

Analyst Color

Price Target

Previews

Reiteration

Analyst Ratings

Trading Ideas

Walmart Q1 Earnings Preview: Why Retailer Will Have 'One Of The Most Telling' Reports On Tariff Impact

Management

STWD

SREIT Appoints Nora Creedon As President And CEO; Succeeds SREIT Appoints Nora Creedon Chief Executive Officer

NVDA closes near high for the day after reversing early weakness
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/14201052/Screenshot-2025-05-14-at-4.10.21%E2%80%AFPM-1021x1024.png" alt="" class="wp-image-12962" /></figure>
Nvidia Inc. (NVDA) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at 10:35 AM on May 14th, a significant trading signal occurred for Nvidia Inc., (NVDA) as it demonstrated a Power Inflow at a price of $132.50. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Nvidia&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Nvidia&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for NVDA, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://tradepulse.net/?utm_source=benzinga&amp;utm_medium=article&amp;utm_campaign=brand_awareness_apr2025">https://tradepulse.net/?utm_source=benzinga&amp;utm_medium=article&amp;utm_campaign=brand_awareness_apr2025</a>, which are responsible for parts of the data within this article.
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved
After Market Close UPDATE:
The price at the time of the Power Inflow was $132.50. The returns on the High price ($135.44) and Close price ($135.34) after the Power Inflow are respectively 2.2% and 2.1%. They were close today but that is not always the case.
Results are not indicative of future results

Equities

Technicals

Opinion

Signals

Nvidia Rises 2.2% After Key Signal, Reversing Early Weakness

CTOR

Citius Oncology Q2 EPS $(0.11) Misses $(0.09) Estimate

SS Innovations (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSII#NASDAQ">SSII</a>) reported quarterly losses of $(0.03) per share. The company reported $5.10 million in sales this quarter.

SSII

SS Innovations Q1 EPS $(0.03), Sales $5.10M

Nauticus Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) reported quarterly losses of $(0.28) per share. The company reported $165.26 thousand in sales this quarter.

KITT

Nauticus Robotics Q1 EPS $(0.28) Up From $(3.96) YoY, Sales $165.26K Down From $464.35M YoY

Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.15) by 20 percent. This is a 91.13 percent increase over losses of $(2.03) per share from the same period last year.

CLDI

Calidi Biotherapeutics Q1 EPS $(0.18) Misses $(0.15) Estimate

Stock Split

SQFTP

SQFTW

Presidio Property Trust Announces 1-For-10 Reverse Stock Split

- PBGENE-DMD is a first-in-class in vivo gene editing approach for the majority of Duchenne Muscular Dystrophy patients impacted by dystrophin mutations in the most common ‘hot spot' region between exons 45-55 -
- Final clinical candidate PBGENE-DMD demonstrates compelling preclinical data for durably improving functional benefit over time -
- Precision targeting to submit an Investigational New Drug (IND) and/or Clinical Trial Application (CTA) for PBGENE-DMD in 2025 with clinical data expected in 2026 -
- Precision to host a webcast and conference call on Thursday, May 15, 2025 at 8:00 AM ET -
Precision BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>), a clinical stage gene editing company utilizing its novel proprietary ARCUS&#xAE; platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced the strategic prioritization and acceleration of PBGENE-DMD, the Company's first-in-class in vivo gene editing approach for Duchenne Muscular Dystrophy (DMD) and highlighted a PBGENE-DMD poster presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting being held May 13-17, 2025, in New Orleans, Louisiana.

Biotech

General

DTIL

Precision BioSciences Accelerates Development Of First-in-Class In Vivo Gene Editing Therapy PBGENE-DMD For Duchenne Muscular Dystrophy Targeting Exons 45–55 Hot Spot, IND/CTA Submission Planned For 2025 And Clinical Data Expected In 2026

Global Water Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWRS#NASDAQ">GWRS</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $0.01 by 100 percent. This is a 33.33 percent decrease over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $12.46 million which beat the analyst consensus estimate of $12.00 million by 3.81 percent. This is a 7.30 percent increase over sales of $11.61 million the same period last year.

GWRS

Global Water Resources Q1 EPS $0.02 Beats $0.01 Estimate, Sales $12.46M Beat $12.00M Estimate

Cisco Systems CFO Scott Herren To Retire Effective July 26, 2025; Mark Patterson To Succeed

First Citizens BancShares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) has outperformed the market over the past 15 years by 4.76% on an annualized basis producing an average annual return of 16.75%. Currently, First Citizens BancShares has a market capitalization of $26.08 billion. 
Buying $100 In FCNCA: If an investor had bought $100 of FCNCA stock 15 years ago, it would be worth $984.91 today based on a price of $1962.92 for FCNCA at the time of writing.
<h3>First Citizens BancShares's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747255516_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FCNCA

Here's How Much $100 Invested In First Citizens BancShares 15 Years Ago Would Be Worth Today

Press Releases

Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Trevi Therapeutics to Participate in Upcoming March Investor Conferences

Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025

Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates

Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

Trevi Therapeutics to Participate in Upcoming April Investor Conferences

Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025

Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

Comments

Trevi Therapeutics

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL